glp-1 patient education pdf Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Receptor Agonists: A Multidisciplinary Expert Consensus The GLP-1 Agonists and Obesity:

Coverage of GLP-1 weight-loss drugs is growing among the largest employers (5000+ workers), now at 43%

Additionally, gastrointestinal side effects (nausea, constipation) may overlap with symptoms of inadequate thyroid hormone replacement, requiring careful clinical differentiation by your healthcare team

However, their effectiveness and risks have not yet been systematically evaluated in a comprehensive set of possible health outcomes

It curbs your appetite You feel full sooner and stay satisfied longer, so you naturally eat less through the day, without feeling hungry all the time

Beyond weight loss, patients typically experience improvements in blood pressure, cholesterol levels, and blood sugar control